Forbes -
6 Jan 2021 15:00

We believe that Nektar Therapeutics stock, a biopharmaceutical company focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain, is a good buying opportunity at the present time. NKTR stock trades near $18 currently and it is, in fact...
Share this Article
Comment on this Article
Please to comment